TURKEY

Image

TURKEY

3,962,760

Total Cases

34,455

Total Deaths

3,424,733

Total Recovered

503,572

Total Active Cases

+273

New Deaths

+59,187

New Cases


via menafn04/04/2021

Turkey registers more than 41 988 new coronavirus cases - MENAFN.COM

Turkey reported 41 988 new coronavirus cases and 185 deaths over the past 24 hours, according to Health Ministry data, Trend reports citing Hurriyet .

The new cases include 1 508 symptomatic patients, while the total number of infections exceeded 3,48 million.

As many as 22 674 people recovered in the past day, bringing the tally to 3 105 350

via wpta2104/03/2021

The Latest: SKorea's daily virus increase tops 500 again - wpta21.com

SEOUL, South Korea — South Korea’s daily increase in coronavirus infections exceeded 500 for the fourth straight day, a pace unseen since January, as experts raise concern about another viral surge amid a slow rollout in vaccines. The 543 new cases reported by the Korea Disease Control and Prevention Agency on Saturday brought the national

via wkow04/02/2021

The Latest: California clears way for indoor concerts, games - WKOW

SEOUL, South Korea — South Korea’s daily increase in coronavirus infections exceeded 500 for the fourth straight day, a pace unseen since January, as experts raise concern about another viral surge amid a slow rollout in vaccines. The 543 new cases reported by the Korea Disease Control and Prevention Agency on Saturday brought the national

via week04/02/2021

The Latest: Poll: People reluctant to get vaccine dose in US - week.com

LINCOLN, Neb. — A 31-year-old Nebraska cattle rancher is recovering after doctors replaced his coronavirus-damaged lungs. The Lincoln Journal-Star reports that Jake Immink, of Fairbury, got sick around Halloween and wound up hospitalized on a ventilator for months. His lungs were so damaged that his only chance for a fairly normal life was a double-lung


via stockholmcf.org03/31/2021

Jailed Turkish academic hospitalized due to COVID-19 - Stockholm Center for Freedom

Renowned Turkish academic and political scientist Prof. Dr. Sedat Laçiner, who was jailed as part of a political crackdown on dissent in the wake of a failed military coup in Turkey on July 15, 2016, has been hospitalized after contracting COVID-19, Turkish Minute reported, citing the Samanyoluhaber news website. According to the report Laçiner’s ward has […]

via finance.yahoo03/29/2021

China reports 15 new COVID-19 cases vs 8 a day earlier - Yahoo Finance

China reported 15 new COVID-19 cases in the mainland for March 28, up from eight a day earlier, the country's national health authority said on Monday. The National Health Commission, in a statement, said all the new cases were imported infections originating from overseas. The number of new asymptomatic cases, which China does not classify as confirmed cases, fell to 18 from 19 a day earlier.

via wbng03/27/2021

The Latest: Navajo Nation extends "safer at home" order - WBNG-TV

WINDOW ROCK, Ariz. — The Navajo Nation has extended and loosened a health order intended to help curb the spread of the coronavirus. Under the latest “safer at home” order issued Friday, the daily curfew hours are 10 p.m. to 5 a.m. MDT and businesses can remain open until 9 p.m. MDT daily, tribal officials

via skysports04/03/2021

Caglar Soyuncu: Leicester defender tests positive for coronavirus while on Turkey duty - Sky Sports

Leicester were without Caglar Soyuncu for Saturday's 2-0 defeat to Manchester City; Soyuncu returned a positive test while on international duty; Leicester are now working with the Turkish Federation to determine when Soyuncu, who is still in Turkey, can return to the UK

via business-standard04/03/2021

Turkey reports record 42,308 new Covid-19 cases, tally surpasses 3.4 mn - Business Standard

Read more about Turkey reports record 42,308 new Covid-19 cases, tally surpasses 3.4 mn on Business-standard. Turkey reported 42,308 new Covid-19 cases in the last 24 hours, the highest level since the beginning of the pandemic, according to its health ministry update on Friday


via wpta2104/02/2021

The Latest: Poll: People reluctant to get vaccine dose in US - wpta21.com

The race is on to vaccinate as many Americans as possible against COVID-19, but a significant number of people in the U.S. are still reluctant to get the shots, even in places where they are plentiful. That’s according to a new poll from The Associated Press-NORC Center for Public Affairs Research. The poll reports that

via football-italia.net04/01/2021

Juventus confirm Demiral tested positive for COVID - Football Italia

Juventus confirm Merih Demiral has returned to Turin and tested positive for COVID. The Bianconeri didn’t release any official statement after reports in Italy claimed the Turkey international had caught COVID while on international duty. Demiral has now returned to Turin and the Old Lady confirmed he’s tested positive for COVID.

via voanews03/30/2021

Turkey's Reliance on Chinese COVID-19 Vaccines Seen as Gamble - Voice of America

Turkey’s announcement of new restrictions in the face of surging COVID-19 infections is putting the spotlight on Ankara’s decision to rely almost solely on Chinese vaccines. With those deliveries repeatedly delayed, there is growing suspicion Beijing could be using the vaccines as leverage — as Dorian Jones reports from Istanbul. Producer: Jon Spier

via menafn03/28/2021

Turkey sends Chinese COVID-19 vaccines to Bosnia-Herzegovina - MENAFN.COM

Some 30,000 doses of the Chinese vaccine Sinovac sent by Turkey arrived in Bosnia-Herzegovina on Sunday to help the country fight the coronavirus outbreak, Trend reports citing Daily Sabah .

The coronavirus vaccines, promised by President Recep Tayyip Erdogan during the Bosnia-Herzegovina Presidential Council members' visit to the capital Ankara on

via menafn03/27/2021

Mutated coronavirus alarms experts as case numbers rise in Turkey - MENAFN.COM

A sudden surge in the number of COVID-19 cases in Turkey cannot be explained away solely with a normalization process, according to experts. Indeed, they point out the greater share of new variants of the virus in coronavirus cases across the country, Trend reports citing Daily Sabah .

Daily cases skyrocketed above 20,000 this week and continue cli


via kutv04/02/2021

Poll: Some in US are reluctant to get COVID-19 vaccines and pandemic roundup - KUTV 2News

The race is on to vaccinate as many Americans as possible against COVID-19, but a significant number of people in the U. S. are still reluctant to get the shots, even in places where they are plentiful. That's according to a new poll from The Associated Press-NORC Center for Public Affairs Research. The poll reports that 25% of Americans say they probably or definitely will not get vaccinated. The holdouts are leery about possible side effects.

via menafn04/02/2021

Turkey registers more than 42 308 new coronavirus cases - MENAFN.COM

Turkey reported 42 308 new coronavirus cases and 179 deaths over the past 24 hours, according to Health Ministry data, Trend reports citing Hurriyet .

The new cases include 1 471 symptomatic patients, while the total number of infections exceeded 3,4 million.

As many as 24 419 people recovered in the past day, bringing the tally to 3 059 462,

via fiercepharma04/02/2021

Sinovac aims to pump out 2B COVID-19 vaccine doses a year, courtesy of third production line - FiercePharma

Just a few months ago, China's Sinovac said it had capacity for just 300 million COVID-19 vaccine doses per year. In February, when the shot scored approval in China, Sinovac said it had lifted annual capacity to 1 billion doses. Now, just one month later, it's doubled that number.

via menafn04/01/2021

Turkey reports 39302 new COVID-19 cases, 3317182 in total - MENAFN.COM

Turkey on Wednesday confirmed 39,302 new COVID-19 cases, including 1,401 symptomatic patients, as the total number of positive cases in the country reached 3,317,182, according to its health ministry, Trend reports citing Xinhua.

The death toll from the virus in Turkey rose by 152 to 31,537, while the total recoveries climbed to 3,014,226 after 19,1

via finance.yahoo03/30/2021

Turkish Ministry of Health Approves Increase in Patient Recruitment into the Phase II Trial for LSALT Peptide - Yahoo Finance

TORONTO, March 30, 2021 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that it received approval from the Turkish Ministry of Health, Pharmaceuticals and Medical Devices Agency (MoH) to recruit up to twenty additional patients into the Phase II trial of its lead drug LSALT peptide (Metablok), targeting acute lung injury and acute kidney injury caused by inflammation in patients with severe cases of COVID-19. The approval from the MoH doubles the number of patients allowed into the Turkish arm of the trial from twenty to forty. The first twenty patients in Turkey have already been recruited into the trial and have completed treatment. Patient recruitment is expected to resume this week in two hospital sites in Istanbul and Ankara. Recent data have shown a second surge in new COVID-19 infections and hospitalizations in Turkey, with a new pandemic high of over 32,000 daily infections reported on March 29, 2021. Turkey experienced a similar surge in daily infections during December 2020. Hospitalization rates are currently at approximately 1% of infected cases, once again putting a strain on the Turkish hospital system. Patient recruitment in this 60-patient phase II trial continues in four clinical sites in Canada and the USA, with 46 patients recruited to date between North America and Turkey. “We appreciate the support of the Turkish Ministry of Health and the enthusiasm of our clinical sites in Turkey to recruit more patients into our trial during this difficult pandemic,” said Richard Muruve, CEO of Arch. About the Phase II trial for LSALT Peptide The Phase II trial is an international, multicenter, randomized, double-blind, placebo-controlled, proof of concept study of LSALT peptide (Metablok) as prevention of organ inflammation known to trigger acute respiratory distress syndrome (ARDS) and acute kidney injury (AKI) in patients infected with SARS-CoV-2 (COVID-19) or new variants of the virus. ARDS is the leading cause of death in COVID-infected patients. AKI has been observed in approximately 35% of patients admitted to hospital with COVID-19 and is also a leading cause of mortality.1 The composite primary endpoint of the Phase II trial reflects the severe effects often experienced by hospitalized COVID-19 patients and deemed appropriate for LSALT peptide’s novel mechanism of action in blocking consequential inflammation in the lungs, kidneys, and other organs. Additional information about the Phase II trial can be found at: https://clinicaltrials.gov/ct2/show/NCT04402957 The Phase II results will be used to design the Phase III program, including greater patient numbers to more fully evaluate efficacy and safety in hospitalized patients at risk to inflammation in the lungs, kidneys or liver. About COVID-19 COVID-19 is the disease caused by the novel coronavirus SARS-CoV-2 that emerged in China in late 2019. Severe complications from COVID-19 are in large part due to excessive host immune responses to the virus that result in progressive lung inflammation and acute respiratory distress syndrome that often requires mechanical ventilation and critical care1. Patients with severe COVID-19 also experience multiple organ dysfunction including acute kidney injury, liver dysfunction, cardiac failure, and blood abnormalities. Treatment of severe COVID-19 has been primarily supportive, relying heavily on respiratory, infectious diseases, and critical care medicine. Survival rates and health care system capacity could both be improved with new treatments that prevent the severe manifestations of COVID-19, such as worsening lung inflammation (ARDS) and AKI experienced by patients infected with SARS-CoV-22 or the many variants that have emerged globally in recent months. 1 Hirsch JS et al. Acute kidney injury in patients hospitalized with COVID-19. Kidney Int. 2020 doi: https://doi.org/10.1016/j.kint.2020.05.006.2 J. S. Ayres, Sci. Adv 10.1126/sciadv.abc1518 (2020) About Arch Biopartners Arch Biopartners Inc. is a clinical stage company focused on the development of innovative technologies that have the potential to make a significant medical or commercial impact. Arch is developing a pipeline of new drug candidates that inhibit inflammation in the lungs, liver and kidneys via the dipeptidase-1 (DPEP-1) pathway for multiple medical indications. Continuing under development in the Arch portfolio are: AB569, a potential new treatment for antibiotic resistant bacterial infections in wounds and the lungs; and ‘Borg’ peptide coatings that increase corrosion resistance and decrease bacterial biofilm on various medical grade metals and plastics. For more information on Arch Biopartners, its technologies and other public documents Arch has filed on SEDAR, please visit www.archbiopartners.com. The Company has 61,462,302 common shares outstanding. Forward-Looking Statements All statements, other than statements of historical fact, in this news release are forward looking statements that involve various risks and uncertainties, including, without limitation, statements regarding the future plans and objectives of the Company. There can be no assurance that such statements will prove to be accurate. Actual results and future events could differ materially from those anticipated in such statements. These and all subsequent written and oral forward-looking statements are based on the estimates and opinions of management on the dates they are made and are expressly qualified in their entirety by this notice. The Company assumes no obligation to update forward-looking statements should circumstances or management’s estimates or opinions change. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release CONTACT: For more information, please contact: Richard Muruve Chief Executive Officer Arch Biopartners, Inc. 647-428-7031 info@archbiopartners.com

via wsiltv03/27/2021

The Latest: Navajo Nation extends "safer at home" order - WSIL TV

WINDOW ROCK, Ariz. — The Navajo Nation has extended and loosened a health order intended to help curb the spread of the coronavirus. Under the latest “safer at home” order issued Friday, the daily curfew hours are 10 p.m. to 5 a.m. MDT and businesses can remain open until 9 p.m. MDT daily, tribal officials